Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Benefits of Neoadjuvant Nivolumab/Chemo Elucidated in NSCLC Exploratory Analysis

June 4th 2023

Neoadjuvant nivolumab plus chemotherapy improved clinical outcomes vs chemotherapy alone in patients with resectable non–small cell lung cancer who received definitive surgery with numerical but not statistical improvements seen even when definitive surgery was not achieved.

TIGIT, PD-1 Bispecific Rilvegostomig Shows Promise Following Prior Immunotherapy Resistance for Advanced PD-L1+ NSCLC

June 4th 2023

The PD-1 and TIGIT bispecific rilvegostomig demonstrated promising early signs of tolerability and efficacy in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer following progression on at least 1 prior checkpoint inhibitor. according to initial findings from the phase 1/2 ARTEMIDE-01 study.

Adjuvant Osimertinib Provides OS Benefit in EGFR+ Stage IB-IIIA NSCLC

June 4th 2023

Treatment with adjuvant osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with resected, EGFR-mutated, stage IB to IIIA non–small cell lung cancer.

Looking at the Latest Data in Lung Cancer at ASCO 2023: Dr Naidoo

June 4th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

BI 764532 Shows Early Efficacy, Manageable Tolerability in DLL3+ SCLC and Neuroendocrine Carcinoma

June 4th 2023

When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC

June 3rd 2023

The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.

ADCs in Development for the Treatment of Lung Cancer

June 2nd 2023

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Overview of Antibody Drug Conjugates in Lung Cancer

June 2nd 2023

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC

June 2nd 2023

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Dr Liu on the Importance of NGS Testing in NSCLC

June 1st 2023

Stephen V. Liu, MD, discusses the importance of next-generation sequencing in non–small cell lung cancer, and details trials that have continued to move this treatment arena forward.

Dr Santos on the Evolution of Osimertinib in EGFR Mutated NSCLC

May 31st 2023

Edgardo S. Santos, MD, FACP, discusses the evolution of osimertinib in the treatment of patients with EGFR-mutated non–small cell lung cancer and the updated data that reaffirmed its role in the adjuvant setting for this patient population.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Dr Santos on the Impact of Cemiplimab With Chemotherapy in Squamous NSCLC

May 30th 2023

Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.

Acclaim-1 Trial of Quaratusugene Ozeplasmid Plus Osimertinib in NSCLC Advances Into Phase 2 Expansion

May 30th 2023

The safety review committee for the phase 1/2 Acclaim-1 trial has ruled that the study evaluating quaratusugene ozeplasmid in combination with osimertinib in patients with advanced non–small cell lung cancer can proceed to the phase 2 expansion portion.

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

May 30th 2023

The FDA has granted priority review to repotrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer.

Dr Park on the Role of Radiation Therapy in NSCLC

May 26th 2023

Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

May 26th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based chemotherapy for patients with resectable non–small cell lung cancer at high risk of recurrence and tumor cell PD-L1 expression of at least 1%.

Advanced NSCLC: Interpreting Data From the POSEIDON Trial

May 26th 2023

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations

May 26th 2023

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

Dr Chiang on Frontline Treatment Combinations in ES-SCLC

May 25th 2023

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.